Clinical Trials Logo
  1. Home
  2. Other
  3. NCT03273374

Intraoperative Radiation Therapy for Resectable Pancreatic Cancer

Resectable Pancreatic Adenocarcinoma Clinical Trial

Official title:
A Prospective, Phase II Study Investigating Efficacy of Intraoperative Radiation Therapy for Resectable Pancreatic Cancer

Clinical Trial Summary

This phase II study is designed to investigate the efficacy of IORT for patients with resectable pancreatic adenocarcinoma. The purpose of the study is to show the local recurrence rate after surgical resection and IORT is superior to that of surgical resection alone from the historical control. A total of 42 patients will be enrolled, and these patients will receive IORT of 10 Gy at 5 millimeter depth of the tumor bed, followed by 6 cycles of adjuvant gemcitabine chemotherapy.

Clinical Trial Description

Treatment outcomes of pancreatic cancer are poor even after surgical resection, thus patients may receive adjuvant chemotherapy or chemoradiotherapy. Intraoperative radiotherapy (IORT) with low energy (50 kV) x-ray allows delivery of a high dose radiation to the tumor bed during surgery while effectively sparing adjacent critical organs. Another advantage of IORT is that delivery of IORT does not interfere with the scheduled administration of adjuvant chemotherapy or chemoradiotherapy. Here we investigate the efficacy of IORT for patients with resectable pancreatic adenocarcinoma by comparing the local recurrence rate after surical resection and IORT with that of surgical resection alone from the historical control. A total of 42 patients will be enrolled in this phase II trial, and these patients will receive IORT of 10 Gy at 5 millimeter depth of the tumor bed, followed by 6 cycles of adjuvant gemcitabine chemotherapy. ;

Study Design

Related Conditions & MeSH terms

  • Resectable Pancreatic Adenocarcinoma
Clinical Trial Details
NCT number NCT03273374
Study type Interventional
Source Gangnam Severance Hospital
Contact
Status Completed
Phase N/A
Start date August 14, 2017
Completion date August 22, 2022
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT04927780 - Perioperative or Adjuvant mFOLFIRINOX for Resectable Pancreatic Cancer Phase 3
Recruiting NCT04940286 - Gemcitabine, Nab-paclitaxel, Durvalumab, and Oleclumab Before Surgery for the Treatment of in Resectable/Borderline Resectable Primary Pancreatic Cancer Phase 2
Enrolling by invitation NCT05754788 - Gene Expression Profile of Resected Pancreatic and Ampullary Adenocarcinoma at Favorable Prognosis
Recruiting NCT05066802 - A Phase 2 Trial of Neoadjuvant Modified FOLFIRINOX Chemotherapy for Resectable Pancreatic Adenocarcinoma Phase 2
Recruiting NCT04858334 - APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation Phase 2
Completed NCT00600002 - Administration as a Biological Adjuvant in Clinically-Staged, Resectable Pancreatic Adenocarcinoma Phase 1
Recruiting NCT03251365 - Intrabdominal Hyperthermic Chemotherapy and Pancreatic Cancer Phase 2/Phase 3
Not yet recruiting NCT06423326 - Gemcitabine, Cisplatin and Nab-Paclitaxel as Neoadjuvant Treatment for Patients With Resectable or Borderline Resectable Pancreatic Cancer Phase 2
Recruiting NCT04340141 - Testing the Use of the Usual Chemotherapy Before and After Surgery for Removable Pancreatic Cancer Phase 3
Recruiting NCT05275075 - Identify microRNAs in Cachexia in Pancreatic Carcinoma
Not yet recruiting NCT06168552 - Fluorescent Navigation Technology in Radical Resection of Pancreatic Cancer Phase 1/Phase 2
Not yet recruiting NCT04915417 - Neoadjuvant Stereotactic Ablative Radiotherapy for Pancreatic Ductal Adenocarcinoma N/A